Macrogenics, Inc.

Krishnan Sampathkumar

Yan Zhou

Stephen James Burke

David Lee Farb

The present disclosure is provides pharmaceutical compositions, for storage and administration, comprising a human PD-1 ('hPD-1') antibody (“retifanlimab”) and buffering agents. The disclosure further provides containers and kits comprising such pharmaceutical compositions. The disclosure further provides the use of such pharmaceutical compositions, containers, and kits containing retifanlimab in the treatment of a cancer, and in certain aspects treatment of a cancer expressing PD-L1.

Pharmaceutical compositions of a PD-1 antibody and use of the same

The present invention is directed in part to pharmaceutical compositions for storage and administration comprising a) a HER2/neu antibody ('margetuximab'), b) buffering agents, and c) stabilizers, wherein said margetuximab is stable. The invention in part provides, containers and kits comprising such pharmaceutical compositions. The invention is directed in part to the use of such pharmaceutical compositions, containers, and kits containing margetuximab in the treatment of HER2/neu-positive cancer (i.e., a cancer that expresses HER2), including breast cancer or gastric cancer or GEJ cancer.

Growing community of inventors

North Potomac, MD, United States of America

Krishnan Sampathkumar